Patterns of care for radiotherapy in vulvar cancer

A gynecologic cancer intergroup study

David K. Gaffney, Andreas Du Bois, Kailash Narayan, Nick Reed, Takafumi Toita, Sandro Pignata, Peter Blake, Lorraine Portelance, Azmat Sadoyze, Richard Potter, Alessandro Colombo, Marcus Randall, Mansoor R. Mirza, Edward L. Trimble

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: This study aimed to describe radiotherapeutic practice in the treatment of vulvar cancer in member study groups of the Gynecologic Cancer Intergroup (GCIG). Methods: A survey was developed and distributed to representatives of the member study groups of the GCIG, targeting the use of radiotherapy (RT) in vulvar cancer. Results: Thirty-two surveys were returned from 12 different cooperative groups. The most common indications for neoadjuvant RT include unresectable disease or International Federation of Gynecology and Obstetrics stage QIII. For the neoadjuvant treatment of vulvar cancer, pelvic doses were 48.2 ± 5.0 Gy (mean ± SD). The upper border of the pelvic field was L4/5 in 4, L5/S1 in 12, and not specified in 4. Of 21 groups that perform neoadjuvant RT, 17 use concomitant chemotherapy and 4 individualize treatment. Weekly cisplatin was the most commonly used chemotherapy. For the neoadjuvant RT treatment of the inguinal region, doses were 49.9 ± 5.5 Gy (mean ± SD). Sixteen of 18 groups used computed tomographic simulation for planning. After initial surgery, the most common indications for RT included positive lymph nodes or positive margins. Chemotherapy was not routinely used after surgery. Conclusions: Doses of RT among GCIG members are similar; however, the indications for treatment, treatment fields, and use of chemotherapy differ somewhat between groups. This is likely due to the rarity of the disease. The lack of randomized trials may contribute to the absence of a broadly accepted standard. This underscores the importance of international cooperation as in GCIG to gather more reliable data for uncommon tumors in gynecologic oncology.

Original languageEnglish
Pages (from-to)163-167
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Vulvar Neoplasms
Radiotherapy
Drug Therapy
Neoplasms
Neoadjuvant Therapy
International Cooperation
Groin
Therapeutics
Gynecology
Cisplatin
Obstetrics
Lymph Nodes

Keywords

  • Chemoradiation
  • Cooperative group
  • Vulva

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Medicine(all)

Cite this

Gaffney, D. K., Du Bois, A., Narayan, K., Reed, N., Toita, T., Pignata, S., ... Trimble, E. L. (2009). Patterns of care for radiotherapy in vulvar cancer: A gynecologic cancer intergroup study. International Journal of Gynecological Cancer, 19(1), 163-167. https://doi.org/10.1111/IGC.0b013e3181996ac3

Patterns of care for radiotherapy in vulvar cancer : A gynecologic cancer intergroup study. / Gaffney, David K.; Du Bois, Andreas; Narayan, Kailash; Reed, Nick; Toita, Takafumi; Pignata, Sandro; Blake, Peter; Portelance, Lorraine; Sadoyze, Azmat; Potter, Richard; Colombo, Alessandro; Randall, Marcus; Mirza, Mansoor R.; Trimble, Edward L.

In: International Journal of Gynecological Cancer, Vol. 19, No. 1, 01.01.2009, p. 163-167.

Research output: Contribution to journalArticle

Gaffney, DK, Du Bois, A, Narayan, K, Reed, N, Toita, T, Pignata, S, Blake, P, Portelance, L, Sadoyze, A, Potter, R, Colombo, A, Randall, M, Mirza, MR & Trimble, EL 2009, 'Patterns of care for radiotherapy in vulvar cancer: A gynecologic cancer intergroup study', International Journal of Gynecological Cancer, vol. 19, no. 1, pp. 163-167. https://doi.org/10.1111/IGC.0b013e3181996ac3
Gaffney, David K. ; Du Bois, Andreas ; Narayan, Kailash ; Reed, Nick ; Toita, Takafumi ; Pignata, Sandro ; Blake, Peter ; Portelance, Lorraine ; Sadoyze, Azmat ; Potter, Richard ; Colombo, Alessandro ; Randall, Marcus ; Mirza, Mansoor R. ; Trimble, Edward L. / Patterns of care for radiotherapy in vulvar cancer : A gynecologic cancer intergroup study. In: International Journal of Gynecological Cancer. 2009 ; Vol. 19, No. 1. pp. 163-167.
@article{d91f7d165fbb4677a5041f958e15f8a1,
title = "Patterns of care for radiotherapy in vulvar cancer: A gynecologic cancer intergroup study",
abstract = "Background: This study aimed to describe radiotherapeutic practice in the treatment of vulvar cancer in member study groups of the Gynecologic Cancer Intergroup (GCIG). Methods: A survey was developed and distributed to representatives of the member study groups of the GCIG, targeting the use of radiotherapy (RT) in vulvar cancer. Results: Thirty-two surveys were returned from 12 different cooperative groups. The most common indications for neoadjuvant RT include unresectable disease or International Federation of Gynecology and Obstetrics stage QIII. For the neoadjuvant treatment of vulvar cancer, pelvic doses were 48.2 ± 5.0 Gy (mean ± SD). The upper border of the pelvic field was L4/5 in 4, L5/S1 in 12, and not specified in 4. Of 21 groups that perform neoadjuvant RT, 17 use concomitant chemotherapy and 4 individualize treatment. Weekly cisplatin was the most commonly used chemotherapy. For the neoadjuvant RT treatment of the inguinal region, doses were 49.9 ± 5.5 Gy (mean ± SD). Sixteen of 18 groups used computed tomographic simulation for planning. After initial surgery, the most common indications for RT included positive lymph nodes or positive margins. Chemotherapy was not routinely used after surgery. Conclusions: Doses of RT among GCIG members are similar; however, the indications for treatment, treatment fields, and use of chemotherapy differ somewhat between groups. This is likely due to the rarity of the disease. The lack of randomized trials may contribute to the absence of a broadly accepted standard. This underscores the importance of international cooperation as in GCIG to gather more reliable data for uncommon tumors in gynecologic oncology.",
keywords = "Chemoradiation, Cooperative group, Vulva",
author = "Gaffney, {David K.} and {Du Bois}, Andreas and Kailash Narayan and Nick Reed and Takafumi Toita and Sandro Pignata and Peter Blake and Lorraine Portelance and Azmat Sadoyze and Richard Potter and Alessandro Colombo and Marcus Randall and Mirza, {Mansoor R.} and Trimble, {Edward L.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1111/IGC.0b013e3181996ac3",
language = "English",
volume = "19",
pages = "163--167",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Patterns of care for radiotherapy in vulvar cancer

T2 - A gynecologic cancer intergroup study

AU - Gaffney, David K.

AU - Du Bois, Andreas

AU - Narayan, Kailash

AU - Reed, Nick

AU - Toita, Takafumi

AU - Pignata, Sandro

AU - Blake, Peter

AU - Portelance, Lorraine

AU - Sadoyze, Azmat

AU - Potter, Richard

AU - Colombo, Alessandro

AU - Randall, Marcus

AU - Mirza, Mansoor R.

AU - Trimble, Edward L.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Background: This study aimed to describe radiotherapeutic practice in the treatment of vulvar cancer in member study groups of the Gynecologic Cancer Intergroup (GCIG). Methods: A survey was developed and distributed to representatives of the member study groups of the GCIG, targeting the use of radiotherapy (RT) in vulvar cancer. Results: Thirty-two surveys were returned from 12 different cooperative groups. The most common indications for neoadjuvant RT include unresectable disease or International Federation of Gynecology and Obstetrics stage QIII. For the neoadjuvant treatment of vulvar cancer, pelvic doses were 48.2 ± 5.0 Gy (mean ± SD). The upper border of the pelvic field was L4/5 in 4, L5/S1 in 12, and not specified in 4. Of 21 groups that perform neoadjuvant RT, 17 use concomitant chemotherapy and 4 individualize treatment. Weekly cisplatin was the most commonly used chemotherapy. For the neoadjuvant RT treatment of the inguinal region, doses were 49.9 ± 5.5 Gy (mean ± SD). Sixteen of 18 groups used computed tomographic simulation for planning. After initial surgery, the most common indications for RT included positive lymph nodes or positive margins. Chemotherapy was not routinely used after surgery. Conclusions: Doses of RT among GCIG members are similar; however, the indications for treatment, treatment fields, and use of chemotherapy differ somewhat between groups. This is likely due to the rarity of the disease. The lack of randomized trials may contribute to the absence of a broadly accepted standard. This underscores the importance of international cooperation as in GCIG to gather more reliable data for uncommon tumors in gynecologic oncology.

AB - Background: This study aimed to describe radiotherapeutic practice in the treatment of vulvar cancer in member study groups of the Gynecologic Cancer Intergroup (GCIG). Methods: A survey was developed and distributed to representatives of the member study groups of the GCIG, targeting the use of radiotherapy (RT) in vulvar cancer. Results: Thirty-two surveys were returned from 12 different cooperative groups. The most common indications for neoadjuvant RT include unresectable disease or International Federation of Gynecology and Obstetrics stage QIII. For the neoadjuvant treatment of vulvar cancer, pelvic doses were 48.2 ± 5.0 Gy (mean ± SD). The upper border of the pelvic field was L4/5 in 4, L5/S1 in 12, and not specified in 4. Of 21 groups that perform neoadjuvant RT, 17 use concomitant chemotherapy and 4 individualize treatment. Weekly cisplatin was the most commonly used chemotherapy. For the neoadjuvant RT treatment of the inguinal region, doses were 49.9 ± 5.5 Gy (mean ± SD). Sixteen of 18 groups used computed tomographic simulation for planning. After initial surgery, the most common indications for RT included positive lymph nodes or positive margins. Chemotherapy was not routinely used after surgery. Conclusions: Doses of RT among GCIG members are similar; however, the indications for treatment, treatment fields, and use of chemotherapy differ somewhat between groups. This is likely due to the rarity of the disease. The lack of randomized trials may contribute to the absence of a broadly accepted standard. This underscores the importance of international cooperation as in GCIG to gather more reliable data for uncommon tumors in gynecologic oncology.

KW - Chemoradiation

KW - Cooperative group

KW - Vulva

UR - http://www.scopus.com/inward/record.url?scp=65649119647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649119647&partnerID=8YFLogxK

U2 - 10.1111/IGC.0b013e3181996ac3

DO - 10.1111/IGC.0b013e3181996ac3

M3 - Article

VL - 19

SP - 163

EP - 167

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 1

ER -